NM_001146079.2:c.488C>T
Variant summary
Our verdict is Likely pathogenic. The variant received 7 ACMG points: 8P and 1B.
The NM_001146079.2(CLDN14):c.488C>T(p.Ala163Val) variant causes a missense change. The variant allele was found at a frequency of 0.000712 in 1,614,124 control chromosomes in the GnomAD database, including 1 homozygotes. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_001146079.2 missense
Scores
Clinical Significance
Conservation
Publications
Genome browser will be placed here
ACMG classification
Our verdict: Likely_pathogenic. The variant received 7 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000434 AC: 66AN: 152236Hom.: 0 Cov.: 33 show subpopulations
GnomAD2 exomes AF: 0.000292 AC: 73AN: 249754 AF XY: 0.000326 show subpopulations
GnomAD4 exome AF: 0.000741 AC: 1083AN: 1461770Hom.: 1 Cov.: 34 AF XY: 0.000719 AC XY: 523AN XY: 727186 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.000433 AC: 66AN: 152354Hom.: 0 Cov.: 33 AF XY: 0.000403 AC XY: 30AN XY: 74500 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Autosomal recessive nonsyndromic hearing loss 29 Pathogenic:6
- -
PM2, PM3, PP1, PP3 -
Variant summary: CLDN14 c.488C>T (p.Ala163Val) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00029 in 249754 control chromosomes (gnomAD), and is commonly reported in individuals of Newfoundland ancestry due to a founder effect (Pater_2017). c.488C>T has been reported in the literature in several individuals affected with Autosomal Recessive Nonsyndromic Hearing Loss, including one compound heterozygous individual (Sloan-Heggen_2016) and several homozygous individuals from 2 unrelated Newfoundland families (Pater_2017). All homozygous individuals had a unique audioprofile that distinguised them from heterozygous and non-carrier family members with unexplained hearing loss (Pater_2017). These data indicate that the variant is very likely to be associated with disease. Four ClinVar submitters have assessed the variant since 2014: one classified the variant as VUS, two as likely pathogenic, and one as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
The CLDN14 c.488C>T (p.Ala163Val) missense variant was identified in a compound heterozygous state with a second missense variant in one individual with nonsyndromic hearing loss (Sloan-Heggen et al. 2016). Pater et al (2017) reported the p.Ala163Val variant in a very large family from Newfoundland that was originally thought to be three separate families but detailed pedigree analysis revealed common ancestors. All ten individuals from this extended family with a rare audioprofile were found to be homozygous for the p.Ala163Val variant. A different audioprofile was identified in five additional individuals in the family with hearing loss. Of these five, one carried the p.Ala163Val variant in a heterozygous state; the remaining four did not carry this variant, and the authors suggest a second cause of hearing loss within the family. Seven additional unaffected members of this family were heterozygous for the p.Ala163Val variant. Analysis by Pater et al. (2017) of additional hearing loss families in Newfoundland revealed the variant in a homozygous state in two related individuals with the same audioprofile as the homozygotes from the extended family, and in a heterozygous state in two further unrelated individuals with hearing loss. The variant was also found in a heterozygous state in an unaffected relative of the two homozygotes. The p.Ala163Val variant was identified in a heterozygous state in four of 175 normal-hearing controls (Pater et al. 2017) and is reported at a frequency of 0.00070 in the European American population of the Exome Sequencing Project. Based on the evidence, the p.Ala163Val variant is classified as likely pathogenic for autosomal recessive nonsyndromic hearing loss. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. -
This sequence variant is a single nucleotide substitution (C>T) at coding position 488 of the CLDN14 gene that results in an alanine to valine amino acid change at residue 163 of the CLDN14 encoded protein, Claudin-14. The Ala163 residue falls in the fourth transmembrane domain (PMID: 27838790). This is a previously reported variant (ClinVar) that has been observed in homozygous and compound heterozygous individuals affected by hearing loss. The alysis of 3 families spanning multiple generations found that this variant, in the homozygous state, associates with hearing loss. This variant is present in 89 of 281,138 (0.03%) alleles in the gnomAD population database. In addition, it is believed to be a founder variant in the Newfoundland island population. Multiple bioinformatic tools predict that this alanine to valine amino acid change would be damaging, and the alanine residue at this position is strongly conserved across the vertebrate species examined. Studies examining the functiol consequence of this variant have not been published, to our knowledge. We consider this a likely pathogenic variant. ACMG Criteria: PM1, PP1, PP3 -
Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with deafness 29 (MIM#614035). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0200 - Variant is predicted to result in a missense amino acid change from alanine to valine. (I) 0252 - This variant is homozygous. (I) 0304 - Variant is present in gnomAD (v2) <0.01 for a recessive condition (89 heterozygotes, 0 homozygotes). (SP) 0501 - Missense variant consistently predicted to be damaging by multiple in silico tools or highly conserved with a major amino acid change. (SP) 0600 - Variant is located in the annotated fourth transmembrane domain (PMID: 27838790). (I) 0705 - No comparable missense variants have previous evidence for pathogenicity. (I) 0802 - This variant has moderate previous evidence of pathogenicity in unrelated individuals. This variant has been classified as a VUS, but has more recently and consistently been classified as likely pathogenic or pathogenic (ClinVar, deafnessvariationdatabase.org). It has been observed in a compound heterozygous individual with congenital-onset nonsyndromic hearing loss (NSHL), and is regarded as a Newfoundland founder variant, having been observed in many homozygous individuals with mid-high frequency NSHL (PMID: 27838790, PMID: 26969326). (SP) 0901 - This variant has strong evidence for segregation with disease. This variant has been observed in a total of twelve homozygous individuals, all linked through haplotype mapping to be part of a single large family (PMID: 27838790). (SP) 1209 - This variant has been shown to be both maternally and paternally inherited (biallelic). (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign -
not provided Pathogenic:2
This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 163 of the CLDN14 protein (p.Ala163Val). This variant is present in population databases (rs143797113, gnomAD 0.06%). This missense change has been observed in individual(s) with autosomal recessive nonsyndromic deafness (PMID: 27838790). It is commonly reported in individuals of Newfoundland ancestry (PMID: 27838790). ClinVar contains an entry for this variant (Variation ID: 228519). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. For these reasons, this variant has been classified as Pathogenic. -
Observed with a pathogenic CLDN14 variant in a patient with hearing loss in published literature, but it is not known whether the variants occurred on the same (in cis) or on different (in trans) chromosomes (PMID: 26969326); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 29447821, 23991001, 36147510, 36833326, 38790217, 27838790, 26969326) -
not specified Uncertain:1
The p.Ala163Val variant in CLDN14 has been previously reported by our laboratory in 1 individual with hearing loss; however, a variant affecting the remaining c opy of CLDN14 was not identified (LMM unpublished data). The variant has been id entified in 29/66382 European chromosomes by the Exome Aggregation Consortium (E xAC, http://exac.broadinstitute.org; dbSNP rs143797113). Although this variant h as been seen in the general population, its frequency is not high enough to rule out a pathogenic role. Computational prediction tools and conservation analysis suggest that this variant may impact the protein, though this information is no t predictive enough to determine pathogenicity. In summary, the clinical signifi cance of the p.Ala163Val variant is uncertain. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at